55 related articles for article (PubMed ID: 17258738)
1. Activin type 2 receptor restoration in MSI-H colon cancer suppresses growth and enhances migration with activin.
Jung BH; Beck SE; Cabral J; Chau E; Cabrera BL; Fiorino A; Smith EJ; Bocanegra M; Carethers JM
Gastroenterology; 2007 Feb; 132(2):633-44. PubMed ID: 17258738
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of activin receptor 2 signalling ameliorates metabolic dysfunction-associated steatotic liver disease in western diet/L-NAME induced cardiometabolic disease.
Swan J; Szabó Z; Peters J; Kummu O; Kemppi A; Rahtu-Korpela L; Konzack A; Hakkola J; Pasternack A; Ritvos O; Kerkelä R; Magga J
Biomed Pharmacother; 2024 May; 175():116683. PubMed ID: 38705130
[TBL] [Abstract][Full Text] [Related]
3. Somatic
Pandzic T; Rendo V; Lim J; Larsson C; Larsson J; Stoimenov I; Kundu S; Ali MA; Hellström M; He L; Lindroth AM; Sjöblom T
Oncotarget; 2017 Nov; 8(58):98646-98659. PubMed ID: 29228717
[TBL] [Abstract][Full Text] [Related]
4. Effects of activin and TGFβ on p21 in colon cancer.
Bauer J; Sporn JC; Cabral J; Gomez J; Jung B
PLoS One; 2012; 7(6):e39381. PubMed ID: 22761777
[TBL] [Abstract][Full Text] [Related]
5. Activin signaling in microsatellite stable colon cancers is disrupted by a combination of genetic and epigenetic mechanisms.
Jung B; Gomez J; Chau E; Cabral J; Lee JK; Anselm A; Slowik P; Ream-Robinson D; Messer K; Sporn J; Shin SK; Boland CR; Goel A; Carethers JM
PLoS One; 2009 Dec; 4(12):e8308. PubMed ID: 20011542
[TBL] [Abstract][Full Text] [Related]
6. Bone morphogenetic proteins, activins, and growth and differentiation factors in tumor immunology and immunotherapy resistance.
Ganjoo S; Puebla-Osorio N; Nanez S; Hsu E; Voss T; Barsoumian H; Duong LK; Welsh JW; Cortez MA
Front Immunol; 2022; 13():1033642. PubMed ID: 36353620
[TBL] [Abstract][Full Text] [Related]
7. An inflammatory response-related gene signature associated with immune status and prognosis of acute myeloid leukemia.
Wu X; Li S; Chen D; Zheng G; Zhang Z; Li Z; Sun X; Zhao Q; Xu J
Am J Transl Res; 2022; 14(7):4898-4917. PubMed ID: 35958446
[TBL] [Abstract][Full Text] [Related]
8. Profiling Activins and Follistatin in Colorectal Cancer According to Clinical Stage, Tumour Sidedness and Smad4 Status.
Refaat B; Zekri J; Aslam A; Ahmad J; Baghdadi MA; Meliti A; Idris S; Sultan S; Alardati H; Saimeh HA; Alsaegh A; Alhadrami M; Hamid T; Naeem ME; Elsamany SA
Pathol Oncol Res; 2021; 27():1610032. PubMed ID: 34867090
[TBL] [Abstract][Full Text] [Related]
9. AT Homopolymer Strings in
Guard J; Rivers AR; Vaughn JN; Rothrock MJ; Oladeinde A; Shah DH
Microorganisms; 2021 Oct; 9(10):. PubMed ID: 34683396
[TBL] [Abstract][Full Text] [Related]
10. Dual Roles of the Activin Signaling Pathway in Pancreatic Cancer.
Qiu W; Kuo CY; Tian Y; Su GH
Biomedicines; 2021 Jul; 9(7):. PubMed ID: 34356885
[TBL] [Abstract][Full Text] [Related]
11. Microsatellite Instability-Related
Zhao L; Zhang J; Qu X; Yang Y; Gong Z; Yang Y; Wu Z; Guo W
Onco Targets Ther; 2020; 13():3809-3821. PubMed ID: 32440149
[TBL] [Abstract][Full Text] [Related]
12. Discovery and Structure-Activity Relationship Study of (
Manz TD; Sivakumaren SC; Ferguson FM; Zhang T; Yasgar A; Seo HS; Ficarro SB; Card JD; Shim H; Miduturu CV; Simeonov A; Shen M; Marto JA; Dhe-Paganon S; Hall MD; Cantley LC; Gray NS
J Med Chem; 2020 May; 63(9):4880-4895. PubMed ID: 32298120
[TBL] [Abstract][Full Text] [Related]
13. Exome-wide somatic mutation characterization of small bowel adenocarcinoma.
Hänninen UA; Katainen R; Tanskanen T; Plaketti RM; Laine R; Hamberg J; Ristimäki A; Pukkala E; Taipale M; Mecklin JP; Forsström LM; Pitkänen E; Palin K; Välimäki N; Mäkinen N; Aaltonen LA
PLoS Genet; 2018 Mar; 14(3):e1007200. PubMed ID: 29522538
[TBL] [Abstract][Full Text] [Related]
14. Activin in acute pancreatitis: Potential risk-stratifying marker and novel therapeutic target.
Staudacher JJ; Yazici C; Carroll T; Bauer J; Pang J; Krett N; Xia Y; Wilson A; Papachristou G; Dirmeier A; Kunst C; Whitcomb DC; Fantuzzi G; Jung B
Sci Rep; 2017 Oct; 7(1):12786. PubMed ID: 28986573
[TBL] [Abstract][Full Text] [Related]
15. Activin signaling is an essential component of the TGF-β induced pro-metastatic phenotype in colorectal cancer.
Staudacher JJ; Bauer J; Jana A; Tian J; Carroll T; Mancinelli G; Özden Ö; Krett N; Guzman G; Kerr D; Grippo P; Jung B
Sci Rep; 2017 Jul; 7(1):5569. PubMed ID: 28717230
[TBL] [Abstract][Full Text] [Related]
16. NFkB is essential for activin-induced colorectal cancer migration via upregulation of PI3K-MDM2 pathway.
Jana A; Krett NL; Guzman G; Khalid A; Ozden O; Staudacher JJ; Bauer J; Baik SH; Carroll T; Yazici C; Jung B
Oncotarget; 2017 Jun; 8(23):37377-37393. PubMed ID: 28418896
[TBL] [Abstract][Full Text] [Related]
17. Microsatellite Instability Pathway and EMAST in Colorectal Cancer.
Carethers JM
Curr Colorectal Cancer Rep; 2017 Feb; 13(1):73-80. PubMed ID: 28367107
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of colorectal cancer oncogene CHRDL2 predicts a poor prognosis.
Sun J; Liu X; Gao H; Zhang L; Ji Q; Wang Z; Zhou L; Wang Y; Sui H; Fan Z; Li Q
Oncotarget; 2017 Feb; 8(7):11489-11506. PubMed ID: 28009989
[TBL] [Abstract][Full Text] [Related]
19. Activins and their related proteins in colon carcinogenesis: insights from early and advanced azoxymethane rat models of colon cancer.
Refaat B; El-Shemi AG; Mohamed AM; Kensara OA; Ahmad J; Idris S
BMC Cancer; 2016 Nov; 16(1):879. PubMed ID: 27835986
[TBL] [Abstract][Full Text] [Related]
20. Commentary: Activin and TGFβ use diverging mitogenic signaling in advanced colon cancer.
Bauer J; Staudacher JJ; Krett NL; Jung B
J Rare Dis Res Treat; 2016; 1(1):43-45. PubMed ID: 27738666
[No Abstract] [Full Text] [Related]
[Next] [New Search]
